Literature DB >> 9869326

Clinical neurochemistry: developments in dementia research based on brain bank material.

E Perry1, J Court, R Goodchild, M Griffiths, E Jaros, M Johnson, S Lloyd, M Piggott, D Spurden, C Ballard, I McKeith, R Perry.   

Abstract

Brain tissue obtained at autopsy continues to provide unique opportunities in current dementia research. Not only is tissue analysis still essential for diagnosis, but investigation of neurochemical pathology, at a level of resolution beyond current in vivo imaging, continues to provide new insights into the involvement of neurotransmitter signalling systems. These are relevant to therapy which, with respect to symptoms such as cognitive impairment, psychosis and depression, is currently targeted to specific transmitter (cholinergic, dopaminergic and serotonergic) systems. This paper focuses on dopaminergic, cholinergic and histaminergic parameters in Alzheimer's disease (AD), Dementia with Lewy bodies (DLB) and Parkinson's disease (PD). In the normal striatum the dopamine transporter and D2 receptor exhibit distinct rostral-caudal distributions and D2 binding is affected by genetic polymorphism at the Taq 1A locus. The transporter is reduced in both DLB and PD but not AD, correlating with severity of extrapyramidal dysfunction, and receptor abnormalities are apparent in DLB patients responding adversely to neuroleptics. Striatal nicotine receptors are lost in all 3 disorders, further reduced as a result of neuroleptic medication, and elevated as a result of tobacco use. In the thalamus there are selective reductions in presynaptic cholinergic activity in DLB in the reticular nucleus which relate to symptoms of hallucinations and fluctuating consciousness prevalent in this disorder. In the hippocampus coupling of muscarinic M1 receptors, relevant to response to cholinergic therapy, is impaired in areas most affected by beta-amyloid plaques and intact in less affected areas. Analysis of histamine H2 receptors indicates that, despite presynaptic histamine abnormalities in AD, receptor numbers are normal. Such clinically and therapeutically relevant observations on human brain neurochemistry provide a basis for improving therapeutic strategies and prospects of diagnostic in vivo chemical imaging.

Entities:  

Mesh:

Year:  1998        PMID: 9869326     DOI: 10.1007/s007020050102

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  15 in total

1.  Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies.

Authors:  Brittany N Dugger; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2010-08-19       Impact factor: 17.088

2.  Regional covariance of muscarinic acetylcholine receptors in Alzheimer's disease using (R, R) [(123)I]-QNB SPECT.

Authors:  Sean J Colloby; Ian G McKeith; David J Wyper; John T O'Brien; John-Paul Taylor
Journal:  J Neurol       Date:  2015-06-30       Impact factor: 4.849

Review 3.  Histamine: A Key Neuromodulator of Memory Consolidation and Retrieval.

Authors:  Hiroshi Nomura; Rintaro Shimizume; Yuji Ikegaya
Journal:  Curr Top Behav Neurosci       Date:  2022

4.  Effects of nicotine and mecamylamine on cognition in rhesus monkeys.

Authors:  Simon N Katner; Sophia A Davis; Amber J Kirsten; Michael A Taffe
Journal:  Psychopharmacology (Berl)       Date:  2004-04-27       Impact factor: 4.530

Review 5.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

6.  Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice.

Authors:  A D Medhurst; J C Roberts; J Lee; C P L-H Chen; S H Brown; S Roman; M K P Lai
Journal:  Br J Pharmacol       Date:  2009-02-16       Impact factor: 8.739

7.  Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease.

Authors:  Suzanne Reeves; Richard Brown; Robert Howard; Paul Grasby
Journal:  Neurology       Date:  2009-02-10       Impact factor: 9.910

Review 8.  M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Shangtong Jiang; Yanfang Li; Cuilin Zhang; Yingjun Zhao; Guojun Bu; Huaxi Xu; Yun-Wu Zhang
Journal:  Neurosci Bull       Date:  2014-03-03       Impact factor: 5.203

9.  AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.

Authors:  Abraham Fisher; Rachel Brandeis; Rachel Haring Nira Bar-Ner; Michal Kliger-Spatz; Niva Natan; Hagar Sonego; Itzhak Marcovitch; Zipora Pittel
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

10.  Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT.

Authors:  Sanjeet Pakrasi; Sean J Colloby; Michael J Firbank; Elaine K Perry; David J Wyper; Jonathan Owens; Ian G McKeith; E David Williams; John T O'Brien
Journal:  J Neurol       Date:  2007-03-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.